New drug combo shows promise for esophageal cancer before surgery
NCT ID NCT07385001
First seen Feb 03, 2026 · Last updated May 06, 2026 · Updated 8 times
Summary
This study is testing whether adding the drug ivonescimab (AK112) to standard chemotherapy before surgery can help shrink tumors in people with advanced esophageal cancer. About 45 adults with resectable, locally advanced esophageal squamous cell carcinoma will receive the combination therapy. The goal is to see if this approach is safe and leads to a major reduction in tumor size before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospitial
RECRUITINGXi'an, Shannxi, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.